The global spinal fusion bone graft substitutes market accounted for USD 3.72 billion in 2023 and is expected to reach at USD 7.42 billion by 2034 with a CAGR of 6.48% during the forecast period 2024-2034. Growing demand for synthetic alternatives, increasing preference for minimally invasive surgeries particularly for treating sports injuries, falls, & road accidents, the expanding elderly population, rising advancements in medical technology, a heightened focus on developing innovative products aimed at improving surgical outcomes, reducing surgical durations, & enhancing patient safety, and surge in regulatory approvals for various spinal fusion bone graft substitutes products are some of the key factors boosting the market growth.
Surge in regulatory approvals for various spinal fusion bone graft substitutes products is predicted to boost the market growth during the forecast period. Materials referred to as spinal fusion bone graft substitutes play a crucial role in promoting bone healing and fusion in spinal surgeries, serving as replacements for traditional autografts or allografts. These substitutes encompass various options, including synthetic bone grafts, demineralized bone matrices, and bone morphogenetic proteins (BMPs). For instance, in July 2023, In order to accommodate the expansion of its products, which include the FDA-approved i-FACTOR bone graft for cervical spinal fusion and a next-generation product that is now being assessed for lumbar spinal fusion - Cerapedics Inc. announced that it has extended its headquarters in the Denver metro region.
By type, demineralized bone matrix was the highest revenue-grossing segment in the global spinal fusion bone graft substitutes market in 2023 owing to the increasing number of elderly individuals, surge in the prevalence of orthopedic conditions, growing demand for technological advancements in demineralized bone matrix, surge in number of innovative products being introduced. For instance, in July 2022, Ossifix Orthopedics has introduced Ossifix Orthopedics DBM/Crunch, a demineralized bone matrix derived entirely from human bone tissue. Additionally, bone morphogenetic proteins is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of sports-related injuries, rising demand for minimally invasive surgical procedures, and surge in technological advancements within the field of bone morphogenetic protein.
By end-user, hospitals was the highest revenue-grossing segment in the global spinal fusion bone graft substitutes market in 2023 owing to the surge in the volume of orthopedic surgeries, including procedures such as spinal fusion, joint reconstruction, & trauma surgeries, significant advancements in technology. Additionally, clinics is predicted to grow at the fastest CAGR during the forecast period owing to the prevalence of musculoskeletal diseases is on the rise, and growing number of innovative product launches. For instance, in February 2022, In order to improve the cervical and lumbar spine fusion procedure, Orthofix Medical Inc. invented Opus B.A., a sophisticated synthetic bioactive bone graft solution.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising incidence of spinal surgeries, increasing collaborations among industry leaders, and surge in approvals for novel medical devices. For instance, in June 2022, Medtronic plc, a prominent player in healthcare technology, has obtained both FDA 510(k) clearance and Breakthrough Device designation for its innovative LigaPASS 2.0 Ligament Augmentation System. LigaPASS stands as the sole FDA-cleared device authorized for ligament augmentation in spinal surgery. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the demand for minimally invasive surgeries, rising adoption of innovative technologies, growing number of advanced product launches, and uptick in approvals by regulatory authorities. For instance, in October 2023, Orthofix Medical Inc., a prominent global provider of spine and orthopedic solutions, has disclosed the full commercial launch of OsteoCove, an innovative bioactive synthetic graft, following its clearance through the FDA's 510k process.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Surge in regulatory approvals for various spinal fusion bone graft substitutes products is predicted to boost the market growth during the forecast period. Materials referred to as spinal fusion bone graft substitutes play a crucial role in promoting bone healing and fusion in spinal surgeries, serving as replacements for traditional autografts or allografts. These substitutes encompass various options, including synthetic bone grafts, demineralized bone matrices, and bone morphogenetic proteins (BMPs). For instance, in July 2023, In order to accommodate the expansion of its products, which include the FDA-approved i-FACTOR bone graft for cervical spinal fusion and a next-generation product that is now being assessed for lumbar spinal fusion - Cerapedics Inc. announced that it has extended its headquarters in the Denver metro region.
By type, demineralized bone matrix was the highest revenue-grossing segment in the global spinal fusion bone graft substitutes market in 2023 owing to the increasing number of elderly individuals, surge in the prevalence of orthopedic conditions, growing demand for technological advancements in demineralized bone matrix, surge in number of innovative products being introduced. For instance, in July 2022, Ossifix Orthopedics has introduced Ossifix Orthopedics DBM/Crunch, a demineralized bone matrix derived entirely from human bone tissue. Additionally, bone morphogenetic proteins is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of sports-related injuries, rising demand for minimally invasive surgical procedures, and surge in technological advancements within the field of bone morphogenetic protein.
By end-user, hospitals was the highest revenue-grossing segment in the global spinal fusion bone graft substitutes market in 2023 owing to the surge in the volume of orthopedic surgeries, including procedures such as spinal fusion, joint reconstruction, & trauma surgeries, significant advancements in technology. Additionally, clinics is predicted to grow at the fastest CAGR during the forecast period owing to the prevalence of musculoskeletal diseases is on the rise, and growing number of innovative product launches. For instance, in February 2022, In order to improve the cervical and lumbar spine fusion procedure, Orthofix Medical Inc. invented Opus B.A., a sophisticated synthetic bioactive bone graft solution.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising incidence of spinal surgeries, increasing collaborations among industry leaders, and surge in approvals for novel medical devices. For instance, in June 2022, Medtronic plc, a prominent player in healthcare technology, has obtained both FDA 510(k) clearance and Breakthrough Device designation for its innovative LigaPASS 2.0 Ligament Augmentation System. LigaPASS stands as the sole FDA-cleared device authorized for ligament augmentation in spinal surgery. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the demand for minimally invasive surgeries, rising adoption of innovative technologies, growing number of advanced product launches, and uptick in approvals by regulatory authorities. For instance, in October 2023, Orthofix Medical Inc., a prominent global provider of spine and orthopedic solutions, has disclosed the full commercial launch of OsteoCove, an innovative bioactive synthetic graft, following its clearance through the FDA's 510k process.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Spinal Fusion Bone Graft Substitutes Market Report 2023 - 2034
Spinal Fusion Bone Graft Substitutes Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Stem Cell Therapy and Visco Supplements
- Synthetic Bone Graft Extenders
- Demineralized Bone Matrix
- Bone Morphogenetic Proteins
Spinal Fusion Bone Graft Substitutes Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Clinics
- Hospitals
- Other
Spinal Fusion Bone Graft Substitutes Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Spinal Fusion Bone Graft Substitutes Market: Type Estimates & Trend Analysis
8. Spinal Fusion Bone Graft Substitutes Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Spinal Fusion Bone Graft Substitutes Market
11. Europe Global Spinal Fusion Bone Graft Substitutes Market
12. Asia Pacific Global Spinal Fusion Bone Graft Substitutes Market
13. Latin America Global Spinal Fusion Bone Graft Substitutes Market
14. MEA Global Spinal Fusion Bone Graft Substitutes Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Stryker
- Arthrex
- Biocomposites
- Baxter
- Wright Medical
- Integra LifeSciences
- Berkeley Advanced Biomaterials
- RTI Surgical
- Bacterin International
- Alphatec
- Johnson & Johnson
- LifeNet Health
- Osteogenics Biomedical
